1. Jul 2026
Description
(AWP Alliance News) - Lonza expanded a strategic collaboration with a US biopharmaceutical company, adding contracts to produce two biologics programs for commercial supply, with options for two more. The long-term deal is captured across a range of contracts with potential to deliver a multi-billion cumulative CHF value.
Work will run across Lonza's US commercial-scale biologics sites, supported by drug substance and drug product capacity in Europe. The partnership includes process intensification such as N-1 perfusion, with planned process optimizations to cut cycle times on selected programs.
https://www.publicnow.com/view/1BEF243F54205A229D5201D3934F3CA35D009A15…
Disclaimer: This news brief was created using generative artificial intelligence. Lonza Group Ltd. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.
